Abstract
Older patients are less likely than younger patients to receive anticoagulation and are more likely to be underanticoagulated. Although the use of warfarin in the elderly has been increasing, fewer than half of eligible patients take warfarin.
Evidence suggests that stroke recurrence in patients on oral anticoagulation is mainly ischemic, and hemorrhagic complications that derive from oral anticoagulation would be related to overdosing.
Several risk factors for developing hemorrhagic complications have been described, and clinical criteria have been designed to help clinicians in decision-making concerning the start of anticoagulation treatment.
Finally, given the promising results of recent studies on new anticoagulant drugs, it is possible that vitamin K antagonists will be replaced in the coming years.
Keywords: Dabigatran etexilate, neuropsychiatric disease, anticoagulation, anticoagulant therapy, very old, Stroke
Cardiovascular & Hematological Disorders-Drug Targets
Title: Anticoagulant Therapy in Very Old Patients
Volume: 11 Issue: 1
Author(s): Rafael G. Davila
Affiliation:
Keywords: Dabigatran etexilate, neuropsychiatric disease, anticoagulation, anticoagulant therapy, very old, Stroke
Abstract: Older patients are less likely than younger patients to receive anticoagulation and are more likely to be underanticoagulated. Although the use of warfarin in the elderly has been increasing, fewer than half of eligible patients take warfarin.
Evidence suggests that stroke recurrence in patients on oral anticoagulation is mainly ischemic, and hemorrhagic complications that derive from oral anticoagulation would be related to overdosing.
Several risk factors for developing hemorrhagic complications have been described, and clinical criteria have been designed to help clinicians in decision-making concerning the start of anticoagulation treatment.
Finally, given the promising results of recent studies on new anticoagulant drugs, it is possible that vitamin K antagonists will be replaced in the coming years.
Export Options
About this article
Cite this article as:
G. Davila Rafael, Anticoagulant Therapy in Very Old Patients, Cardiovascular & Hematological Disorders-Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187152911795945196
DOI https://dx.doi.org/10.2174/187152911795945196 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heart Failure in East Asia
Current Cardiology Reviews Oxidative Stress in Cardiovascular Disease: A New Avenue Toward Future Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Functional and Structural Alterations of Large Arteries: Methodological Issues
Current Pharmaceutical Design Empagliflozin and the Diabetic Kidney: Pathophysiological Concepts and Future Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Antioxidants as a Preventive Treatment for Epileptic Process: A Review of the Current Status
Current Neuropharmacology Basal Septal Hypertrophy
Current Cardiology Reviews Management of Incidental Findings in the Era of Next-generation Sequencing
Current Genomics Imidazoline Receptor Agonists in Obesity-Related Hypertension: Therapeutic Targeting of the Sympathetic Nervous System
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design Mouse Mutants of Relaxin, Insulin-Like 3 Peptide and their Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Emerging Anticoagulants
Current Medicinal Chemistry Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Peripartum Cardiomyopathy: An Intensivist's Perspective
Current Women`s Health Reviews Does A Subclinical Cardiotoxic Effect of Clozapine Exist? Results from a Follow-up Pilot Study
Cardiovascular & Hematological Agents in Medicinal Chemistry A Combined Approach Using Patch-Clamp Study and Computer Simulation Study for Understanding Long QT Syndrome and TdP in Women
Current Cardiology Reviews Platelet-Derived Chemokines in Atherogenesis: What’s New?
Current Vascular Pharmacology